Skip to main content
SpringerLink
Log in

Detection of Single Nucleotide Polymorphisms in the ABCG2 Gene in a Dutch Population

  • Original Research Article
  • Published:
American Journal of Pharmacogenomics

Abstract

Background

ABCG2 is a drug transporter involved in the protection of tissues by actively transporting toxic substances and xenobiotics out of cells. Cancer cells overexpressing the ABCG2 gene show multidrug resistance to mitoxantrone-, methotrexate-, doxorubicin-, and camptothecin-based anticancer drugs, such as topotecan and SN-38. Large interindividual differences have been shown in oral availability and clearance of drugs that are substrates for ABCG2. Variation in the ABCG2 gene, such as single nucleotide polymorphisms (SNPs), can possibly explain the variability in pharmacokinetics of ABCG2 substrates.

Aim

This study was performed to screen for SNPs in the ABCG2 gene to determine the frequencies of currently known and previously unknown SNPs in a Dutch population.

Methods

Blood samples were obtained from 100 healthy volunteers to isolate genomic DNA. PCR amplification was performed, followed by DNA sequencing. The population, of which the ethnicity was 93% Caucasian, consisted of 79 female individuals and 21 males.

Results

In total, 19 SNPs were found in the ABCG2 gene, of which 7 were previously unknown. The SNPs G8883A in exon 5 and C44168T in exon 14 cause an amino acid change of R160Q and R575X, respectively. Most of the previously unknown SNPs were found in introns.

Conclusions

The results will be used in future studies to explore the influence of the different SNPs on ABCG2 protein expression, activity, and substrate specificity. In addition, the results can be used to study the effects of genetic polymorphisms in the ABCG2 gene on the pharmacokinetic profile of anticancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Table III
Table IV
Fig. 3

Similar content being viewed by others

References

  1. Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002 Oct; 198(2): 213–9

    Article  PubMed  CAS  Google Scholar 

  2. Bailey-Dell KJ, Hassel B, Doyle LA, et al. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001 Sep 21; 1520(3): 234–41

    Article  PubMed  CAS  Google Scholar 

  3. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002 Apr; 1(6): 427–34

    PubMed  CAS  Google Scholar 

  4. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003 Jan; 13(1): 19–28

    Article  PubMed  CAS  Google Scholar 

  5. Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 2002 Oct; 3(5): 503–11

    Article  PubMed  CAS  Google Scholar 

  6. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001 Sep 15; 61(18): 6635–9

    PubMed  CAS  Google Scholar 

  7. Mitomo H, Kato R, Ito A, et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 2003 Aug 1; 373 (Pt 3): 767–74

    Article  PubMed  CAS  Google Scholar 

  8. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003 Jan 21; 55(1): 125–32

    Article  PubMed  CAS  Google Scholar 

  9. Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004 May 7; 279(19): 19781–9

    Article  PubMed  CAS  Google Scholar 

  10. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001 Apr 15; 61(8): 3458–64

    PubMed  CAS  Google Scholar 

  11. Cooray HC, Blackmore CG, Maskell L, et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002 Nov 15; 13(16): 2059–63

    Article  PubMed  CAS  Google Scholar 

  12. Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 2000 Apr 29; 271(1): 42–6

    Article  PubMed  CAS  Google Scholar 

  13. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein: potential clinical implications. Ann NY Acad Sci 2000, 94

    Google Scholar 

  14. Volk EL, Farley KM, Wu Y, et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002 Sep 1; 62(17): 5035–40

    PubMed  CAS  Google Scholar 

  15. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999 Sep 1; 59(17): 4237–41

    PubMed  CAS  Google Scholar 

  16. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000 Oct 18; 92(20): 1651–6

    Article  PubMed  CAS  Google Scholar 

  17. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002 Jul 1; 20(13): 2943–50

    Article  PubMed  CAS  Google Scholar 

  18. Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002; 7(6): 516–30

    Article  PubMed  CAS  Google Scholar 

  19. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002 Jun; 1(8): 611–6

    PubMed  CAS  Google Scholar 

  20. Bäckström G, Taipalensuu J, Melhus H, et al. Genetic variation in the ATP-binding Cassette Transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003 Apr; 18(5): 359–64

    Article  PubMed  Google Scholar 

  21. Iida A, Saito S, Sekine A, et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 2002; 47(6): 285–310

    Article  PubMed  CAS  Google Scholar 

  22. Honjo Y, Morisaki K, Huff LM, et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002 Nov; 1(6): 696–702

    PubMed  CAS  Google Scholar 

  23. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990 Mar; 28(3): 495–503

    PubMed  CAS  Google Scholar 

  24. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004 Mar 20; 109(2): 238–46

    Article  PubMed  CAS  Google Scholar 

  25. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004 Jul; 76(1): 38–44

    Article  PubMed  CAS  Google Scholar 

  26. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003 Sep 1; 63(17): 5538–43

    PubMed  CAS  Google Scholar 

  27. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003 Jul 15; 63(14): 4048–54

    PubMed  CAS  Google Scholar 

  28. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the bcrp1 (abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 2002 Apr 15; 62(8): 2294–9

    PubMed  CAS  Google Scholar 

  29. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003 Nov 17; 89(10): 1971–8

    Article  PubMed  CAS  Google Scholar 

  30. Kobayashi D, Ieiri I, Hirota T, et al. Functional assessment fo ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005 Jan; 33(1): 94–101

    Article  PubMed  CAS  Google Scholar 

  31. Kawabata S, Oka M, Soda H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003 Aug 1; 9(8): 3052–7

    PubMed  CAS  Google Scholar 

  32. Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999 Mar 3; 91(5): 429–33

    Article  PubMed  CAS  Google Scholar 

  33. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002 Jan; 2(1): 48–58

    Article  PubMed  CAS  Google Scholar 

  34. Sargent JM, Williamson CJ, Maliepaard M, et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001 Nov; 115(2): 257–62

    Article  PubMed  CAS  Google Scholar 

  35. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002 May; 16(5): 833–9

    Article  PubMed  Google Scholar 

  36. Steinbach D, Sell W, Voigt A, et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002 Aug; 16(8): 1443–7

    Article  PubMed  CAS  Google Scholar 

  37. Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002 Apr; 8(4): 1068–74

    PubMed  CAS  Google Scholar 

  38. Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000 Jul 1; 96(1): 365–8

    PubMed  CAS  Google Scholar 

  39. Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004 Mar 1; 10(5): 1691–7

    Article  PubMed  CAS  Google Scholar 

  40. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001 Apr; 92(4): 452–8

    Article  PubMed  CAS  Google Scholar 

  41. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002 May; 55(5): 332–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work has been supported in part by a grant from Aventis Pharma BV, The Netherlands.

Author information

Authors and Affiliations

  1. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, 1066 EC, The Netherlands

    Tessa M. Bosch, Linda M. Kjellberg & Jos H. Beijnen

  2. Department of Molecular Biology, Slotervaart Hospital, Amsterdam, The Netherlands

    Anja Bouwers & Paul H. M. Smits

  3. Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

    Bobby P. C. Koeleman

  4. Department of Biomedical Analysis, University of Utrecht, Faculty of Pharmaceutical Sciences, Utrecht, The Netherlands

    Jan H. M. Schellens, Jos H. Beijnen & Irma Meijerman

  5. Medical Oncology Department, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    Jan H. M. Schellens

Authors
  1. Tessa M. Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda M. Kjellberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anja Bouwers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bobby P. C. Koeleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan H. M. Schellens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul H. M. Smits
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Irma Meijerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tessa M. Bosch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bosch, T.M., Kjellberg, L.M., Bouwers, A. et al. Detection of Single Nucleotide Polymorphisms in the ABCG2 Gene in a Dutch Population . Am J Pharmacogenomics 5, 123–131 (2005). https://doi.org/10.2165/00129785-200505020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129785-200505020-00005

Keywords

Search

Navigation